Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Male or non-pregnant, non-lactating female patients at least 18 years of age~Diagnosis of moderate to severe AS with prior documented radiologic evidence (x-ray or radiologist's report) fulfilling the Modified New York criteria for AS:~* Active AS assessed by BASDAI ≥4 (0-10) at Baseline~* Spinal pain as measured by BASDAI question #2 ≥ 4 cm (0-10 cm) at Baseline~* Total back pain as measured by VAS ≥ 40 mm (0-100 mm) at Baseline Patients should have had inadequate response or failure to respond to at least 2 NSAIDs at an approved dose for a minimum of 4 weeks in total and a minimum of 2 weeks for each NSAID prior to randomization, or less than 4 weeks if therapy had to be withdrawn due to intolerance, toxicity or contraindications Patients who are regularly taking NSAIDs (including COX-1 or COX-2 inhibitors) as part of their AS therapy are required to be on a stable dose for at least 2 weeks before randomisation Patients who have been on a TNFα inhibitor (not more than one) must have experienced an inadequate response to previous or current treatment given at an approved dose for at least 3 months prior to randomization or have been intolerant to at least one administration of an anti-TNFα agent~Exclusion Criteria:~* Chest X-ray or MRI with evidence of ongoing infectious or malignant process~  * Patients taking high potency opioid analgesics~ * Previous exposure to secukinumab or any other biologic drug directly targeting IL-17 or IL-17 receptor~ * Pregnant or nursing (lactating) women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Secukinumab (Type: EXPERIMENTAL): Secukinumab 150 mg s.c.~Arm includes all patients who received at least 1 dose of study drug including placebo switchers at Week 16
- Placebo (Type: PLACEBO_COMPARATOR): Placebo s.c.

Based on this trial design, predict the completion outcome and termination type (if applicable).